ArticleNeuro-oncology advances
Predictive value of brain tumor reporting and data system scores for functional outcomes and progression-free survival in glioblastoma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Brain Tumor Reporting and Data System (BT-RADS) is a standardized reporting system developed for routine clinical use for MRI interpretation in patients with primary brain tumors. This study evaluates the BT-RADS predictive value in glioblastoma (GBM) for patient functional outcomes assessed through the Karnofsky Performance Scale (KPS) score and PFS. Methods: This retrospective study includes 94 adult patients with newly diagnosed GBM at Emory University Hospital from January 2019 to January 2023. Predictor variables included BT-RADS scores recorded from MRIs ∼3 months (BT-RADS_A) and ∼9 months post-resection or biopsy (BT-RADS_B), with scores classified as low (BT-RADS score 0-3a) or high (BT-RADS score 3b-4). Outcome variables included PFS and KPS scores at 1 year post-diagnosis, with scores of 70-100% classified as favorable and 0-60% classified as unfavorable. Covariates included O6-methylguanine-DNA methyltransferase ( Results: In a univariate logistic regression analysis, BT-RADS_A was a significant predictor ( Conclusions: BT-RADS scores can predict functional outcomes and PFS in newly diagnosed GBM patients at ∼3 and ∼9 months post-diagnosis. Future studies are warranted to validate these findings and refine predictive models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.